Science

Older adults who stop statins face higher heart event risks, study finds

The STREAM clinical trial found older patients who discontinued statin therapy experienced more heart attacks, strokes, and deaths than those who continued their medication.

Orange prescription bottle lot
Haley Lawrence / Unsplash, Unsplash License

CHICAGO — Older adults without a history of cardiovascular disease who stop taking statins face a slightly higher risk of heart attacks, strokes, and death compared to those who remain on therapy, according to results from the STREAM clinical trial presented at the American Heart Association Scientific Sessions 2026 and published Nov. 7 in the New England Journal of Medicine.

The study evaluated whether adults aged 70 and older could safely discontinue cholesterol-lowering medications prescribed for primary prevention. Although authors reported that stopping the medication satisfied pre-established statistical criteria for noninferiority, patients assigned to halt statins experienced more cardiovascular events over a two-year period than those who continued daily treatment.

Higher rate of heart events after stopping statins

The study was led by Dr. Nicolas Rodondi, a researcher at Switzerland’s University of Bern. Investigators tracked 1,880 participants who were at least 70 years old, with an average age of 77.5. Every participant had two or more chronic health issues but no established history of cardiovascular illness. Subjects were randomly assigned to either cease or maintain statin treatment, with researchers monitoring them for a median duration of 103 weeks.

The data revealed that 12.7 percent of patients who stopped statins suffered a nonfatal heart attack, nonfatal stroke, or died. In contrast, 9.2 percent of participants who remained on medication experienced one of those outcomes. This absolute difference of 3.5 percentage points represented roughly 38 percent more relative events among those who discontinued therapy.

Rodondi calculated that over two years, discontinuing statin use led to one additional major cardiovascular incident or death for every 40 patients. Furthermore, 43 percent of patients in the discontinuation group experienced serious adverse events, compared to 39.8 percent in the group that continued therapy.

No improvements in physical symptoms or quality of life

Patients frequently ask about stopping statins because of concerns regarding muscle aches and other potential side effects. However, trial metrics revealed no physical benefits from ending treatment.

Researchers evaluated muscle discomfort, incidence of falls, general quality of life, and sarcopenia, which is the progressive loss of muscle strength and mass. The analysis showed no significant differences between the two study groups in any of these areas, indicating that stopping statins did not relieve physical symptoms or enhance well-being.

Following the trial, an independent data and safety monitoring board recommended that participants who had been assigned to discontinue statins consult their physicians about restarting the medication.

Physicians advise shared decision-making

Medical experts cautioned patients against unilaterally stopping their cholesterol medications based on the trial’s noninferiority designation.

“This small, increased risk of cardiovascular events means that one cannot make a general recommendation about stopping statins in this patient population,” study coauthor Dr. Rita F. Redberg of the University of California, San Francisco, said in a statement. She explained that patients and doctors should decide together whether stopping is appropriate, though noting discontinuation remains generally safe for most older adults without prior cardiovascular events.

Cardiologists, including Dr. Dmitry Yaranov, noted that statistical noninferiority does not mean both strategies produced equal outcomes. Doctors emphasized that any decision to stop statins should factor in an individual’s overall health, frailty, life expectancy, and side effects rather than age alone.

Cardiologists also stressed that the STREAM trial focused solely on primary prevention. Patients who take statins for secondary prevention — because they have already survived a stroke or heart attack — face heightened risks if they discontinue medication without medical guidance.